يعرض 1 - 20 نتائج من 107 نتيجة بحث عن '"D, Cella"', وقت الاستعلام: 0.60s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal

    المساهمون: Eisai (Натли, штат Нью-Джерси, США), Merck Sharp & Dohme, дочерняя компания Merck & Co (Кенилворт, штат НьюДжерси, США)

    المصدر: Cancer Urology; Том 18, № 2 (2022); 39-57 ; Онкоурология; Том 18, № 2 (2022); 39-57 ; 1996-1812 ; 1726-9776

    وصف الملف: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/1607/1366; Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473–82. DOI:10.1016/S1470-2045(15)00290-9; McDermott D.F., Lee J.L., Bjarnason G.A. et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J Clin Oncol 2021;39(9):1020–8. DOI:10.1200/JCO.20.02363; Lee C.H., Shah A.Y., Rasco D. et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 2021;22(7):946–58. DOI:10.1016/S1470-2045(21)00241-2; Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289–300. DOI:10.1056/NEJMoa2035716; Motzer R.J., Jonasch E., Agarwal N. et al. Kidney cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20(1):71–90. DOI:10.6004/jnccn.2022.0001; Powles T., Albiges L., Bex A. et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 2021;32(12):1511–19. DOI:10.1016/j.annonc.2021.09.014; Merck Sharp & Dohme. Keytruda® (pembrolizumab) package insert. Whitehouse Station, NJ, USA: Merck Sharp & Dohme, 2021.; Eisai. Lenvima® (lenvatinib) package insert. Nutley, NJ, USA: Eisai, 2021.; Padala S.A., Kallam A. Clear cell renal carcinoma. StatPearls. Treasure Island, FL: StatPearls Publishing, 2021.; Song X.D., Tian Y.N., Li H. et al. Research progress on advanced renal cell carcinoma. J Int Med Res 2020;48(6):300060520924265. DOI:10.1177/0300060520924265; Kekäle M., Peltoniemi M., Airaksinen M. Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 2015;9:1733–40. DOI:10.2147/PPA.S92125; Yu S.T., Ge J.N., Luo J.Y. et al. Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis. Cancer Manag Res 2019;11:1525–32. DOI:10.2147/CMAR.S191499; Cabanillas M.E., Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodinerefractory differentiated thyroid cancer. Semin Oncol 2019;46(1):57–64. DOI:10.1053/j.seminoncol.2018.11.004; Ellithi M., Elnair R., Chang G.V., Abdallah M.A. Toxicities of immune checkpoint inhibitors: itis-ending adverse reactions and more. Cureus 2020;12(2):e6935. DOI:10.7759/cureus.6935; Zhou K., Fountzilas C. Outcomes and quality of life of systemic therapy in advanced hepatocellular carcinoma. Cancers (Basel) 2019;11(6):861. DOI:10.3390/cancers11060861; Cella D., Yount S., Brucker P.S. et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 2007;10(4):285–93. DOI:10.1111/j.1524-4733.2007.00183.x; Aaronson N.K., Ahmedzai S., Bergman B. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365–76. DOI:10.1093/jnci/85.5.365; Rabin R., de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33(5):337–43. DOI:10.3109/07853890109002087; Cella D., Motzer R.J., Suarez C. et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(2):292–303. DOI:10.1016/S1470-2045(21)00693-8; Cella D., Grünwald V., Escudier B. et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol 2019;20(2):297–310. DOI:10.1016/S1470-2045(18)30778-2; Choueiri T.K., Powles T., Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829–41. DOI:10.1056/NEJMoa2026982; Bedke J., Rini B., Plimack E. et al. Health-related quality-of-life (HRQoL) analysis from KEYNOTE-426: pembrolizumab (pembro) plus axitinib (axi) vs sunitinib for advanced renal cell carcinoma (RCC). European Association of Urology (EAU20) Virtual Congress. July 17–26, 2020.; Cella D., Li J.Z., Cappelleri J.C. et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008;26(22):3763–9. DOI:10.1200/JCO.2007.13.5145; Osoba D., Rodrigues G., Myles J. et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16(1):139–44. DOI:10.1200/JCO.1998.16.1.139; Pickard A.S., De Leon M.C., Kohlmann T. et al. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 2007;45(3):259–63. DOI:10.1097/01.mlr.0000254515.63841.81; Choueiri T.K., Powles T., Porta C. et al. A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a firstline treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study). Kidney Cancer Research Summit (KCRS21). Oct 7–8, 2021.; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. DOI:10.1056/NEJMoa1816714; European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Assessement report, procedure no. EMEA/H/C/003820/II/0069. July 25, 2019. Available at: https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0069-epar-assessment-report-variation_en.pdf (accessed Nov 8, 2021).; https://oncourology.abvpress.ru/oncur/article/view/1607

  4. 4
  5. 5
  6. 6
  7. 7

    المؤلفون: Rachel L. Miller, Holly Schuh, Aruna Chandran, Izzuddin M. Aris, Casper Bendixsen, Jeffrey Blossom, Carrie Breton, Carlos A. Camargo, Glorisa Canino, Kecia N. Carroll, Sarah Commodore, José F. Cordero, Dana M. Dabelea, Assiamira Ferrara, Rebecca C. Fry, Jody M. Ganiban, James E. Gern, Frank D. Gilliland, Diane R. Gold, Rima Habre, Marion E. Hare, Robyn N. Harte, Tina Hartert, Kohei Hasegawa, Gurjit K. Khurana Hershey, Daniel J. Jackson, Christine Joseph, Jean M. Kerver, Haejin Kim, Augusto A. Litonjua, Carmen J. Marsit, Cindy McEvoy, Eneida A. Mendonça, Paul E. Moore, Flory L. Nkoy, Thomas G. O’Connor, Emily Oken, Dennis Ownby, Matthew Perzanowski, Katherine Rivera-Spoljaric, Patrick H. Ryan, Anne Marie Singh, Joseph B. Stanford, Rosalind J. Wright, Robert O. Wright, Antonella Zanobetti, Edward Zoratti, Christine C. Johnson, P.B. Smith, K.L. Newby, L.P. Jacobson, D.J. Catellier, R. Gershon, D. Cella, A. Alshawabkeh, J. Aschner, S. Merhar, C. Ren, A. Reynolds, R. Keller, G. Pryhuber, A. Duncan, A. Lampland, R. Wadhawan, C. Wagner, M. Hudak, D. Mayock, L. Walshburn, S.L. Teitelbaum, A. Stroustrup, L. Trasande, C. Blair, L. Gatzke-Kopp, M. Swingler, J. Mansbach, J. Spergel, H. Puls, M. Stevenson, C. Bauer, S. Deoni, C. Duarte, A. Dunlop, A. Elliott, L. Croen, L. Bacharier, G. O’Connor, M. Kattan, R. Wood, G. Hershey, D. Ownby, I. Hertz-Picciotto, A. Hipwell, M. Karagas, C. Karr, A. Mason, S. Sathyanarayana, B. Lester, B. Carter, C. Neal, L. Smith, J. Helderman, L. Leve, J. Ganiban, J. Neiderhiser, S. Weiss, R. Zeiger, R. Tepper, K. Lyall, R. Landa, S. Ozonoff, R. Schmidt, S. Dager, R. Schultz, J. Piven, H. Volk, R. Vaidya, R. Obeid, C. Rollins, K. Bear, S. Pastyrnak, M. Lenski, M. Msall, J. Frazier, L. Washburn, A. Montgomery, C. Barone, P. McKane, N. Paneth, M. Elliott, J. Herbstman, S. Schantz, C. Porucznik, R. Silver, E. Conradt, M. Bosquet-Enlow, K. Huddleston, N. Bush, R. Nguyen, T. O'Connor, M. Samuels-Kalow

    المصدر: Journal of Allergy and Clinical Immunology.

    مصطلحات موضوعية: Immunology, Immunology and Allergy

  8. 8
  9. 9
  10. 10
  11. 11

    المصدر: Value in Health. 24:862-873

  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    Academic Journal
  17. 17
  18. 18
    Academic Journal

    المساهمون: The Pennsylvania State University CiteSeerX Archives

    المصدر: ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/81/97/Qual_Life_Res_2010_Oct_15_19(8)_1181-1184.tar.gz

    وصف الملف: application/zip

  19. 19
    Academic Journal

    المساهمون: The Pennsylvania State University CiteSeerX Archives

    المصدر: ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/88/b9/Qual_Life_Res_2009_Sep_19_18(7)_873-880.tar.gz

    وصف الملف: application/zip

  20. 20